bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management
Authors: McGee Rose B. , Oak Ninad , Harrison Lynn , Xu Ke , Nuccio Regina , Blake Alise K. , Mostafavi Roya , Lewis Sara , Taylor Leslie M. , Kubal Manish , Ouma Annastasia , Hines-Dowell Stacy J. , Cheng Cheng , Furtado Larissa V. , Nichols Kim E.
Published: April 2023

AbstractPurpose:
Clinical genomic sequencing of pediatric tumors is increasingly uncovering pathogenic variants in adult-onset cancer predisposition genes (aoCPG). Nevertheless, it remains poorly understood how often aoCPG variants are of germline origin and whether they influence tumor molecular profiles and/or clinical care. In this study, we examined the prevalence, spectrum, and impacts of aoCPG variants on tumor genomic features and patient management at our institution.
Experimental Design:
This is a retrospective study of 1,018 children with cancer who underwent clinical genomic sequencing of their tumors. Tumor genomic data were queried for pathogenic variants affecting 24 preselected aoCPGs. Available tumor whole-genome sequencing (WGS) data were evaluated for second hit mutations, loss of heterozygosity (LOH), DNA mutational signatures, and homologous recombination deficiency (HRD). Patients whose tumors harbored one or more pathogenic aoCPG variants underwent subsequent germline testing based on hereditary cancer evaluation and family or provider preference.
Results:
Thirty-three patients (3%) had tumors harboring pathogenic variants affecting one or more aoCPGs. Among 21 tumors with sufficient WGS sequencing data, six (29%) harbored a second hit or LOH affecting the remaining aoCPG allele with four of these six tumors (67%) also exhibiting a DNA mutational signature consistent with the altered aoCPG. Two additional tumors demonstrated HRD, of uncertain relation to the identified aoCPG variant. Twenty-one of 26 patients (81%) completing germline testing were positive for the aoCPG variant in the germline. All germline-positive patients were counseled regarding future cancer risks, surveillance, and risk-reducing measures. No patients had immediate cancer therapy changed due to aoCPG data.
Conclusions:
AoCPG variants are rare in pediatric tumors; however, many originate in the germline. Almost one third of tumor aoCPG variants examined exhibited a second hit and/or conferred an abnormal DNA mutational profile suggesting a role in tumor formation. aoCPG information aids in cancer risk prediction but is not commonly used to alter the treatment of pediatric cancers.
Data from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
Authors: Vasudev Naveen S. , Scelo Ghislaine , Glennon Kate I. , Wilson Michelle , Letourneau Louis , Eveleigh Robert , Nourbehesht Nazanin , Arseneault Madeleine , Paccard Antoine , Egevad Lars , Viksna Juris , Celms Edgars , Jackson Sharon M. , Abedi-Ardekani Behnoush , Warren Anne Y. , Selby Peter J. , Trainor Sebastian , Kimuli Michael , Cartledge Jon , Soomro Naeem , Adeyoju Adebanji , Patel Poulam M. , Wozniak Magdalena B. , Holcatova Ivana , Brisuda Antonin , Janout Vladimir , Chanudet Estelle , Zaridze David , Moukeria Anush , Shangina Oxana , Foretova Lenka , Navratilova Marie , Mates Dana , Jinga Viorel , Bogdanovic Ljiljana , Kovacevic Bozidar , Cambon-Thomsen Anne , Bourque Guillaume , Brazma Alvis , Tost Jörg , Brennan Paul , Lathrop Mark , Riazalhosseini Yasser , Banks Rosamonde E.
Published: April 2023

AbstractPurpose:
Patients with resected localized clear-cell renal cell carcinoma (ccRCC) remain at variable risk of recurrence. Incorporation of biomarkers may refine risk prediction and inform adjuvant treatment decisions. We explored the role of tumor genomics in this setting, leveraging the largest cohort to date of localized ccRCC tissues subjected to targeted gene sequencing.
Experimental Design:
The somatic mutation status of 12 genes was determined in 943 ccRCC cases from a multinational cohort of patients, and associations to outcomes were examined in a Discovery (n = 469) and Validation (n = 474) framework.
Results:
Tumors containing a von-Hippel Lindau (VHL) mutation alone were associated with significantly improved outcomes in comparison with tumors containing a VHL plus additional mutations. Within the Discovery cohort, those with VHL+0, VHL+1, VHL+2, and VHL+≥3 tumors had disease-free survival (DFS) rates of 90.8%, 80.1%, 68.2%, and 50.7% respectively, at 5 years. This trend was replicated in the Validation cohort. Notably, these genomically defined groups were independent of tumor mutational burden. Amongst patients eligible for adjuvant therapy, those with a VHL+0 tumor (29%) had a 5-year DFS rate of 79.3% and could, therefore, potentially be spared further treatment. Conversely, patients with VHL+2 and VHL+≥3 tumors (32%) had equivalent DFS rates of 45.6% and 35.3%, respectively, and should be prioritized for adjuvant therapy.
Conclusions:
Genomic characterization of ccRCC identified biologically distinct groups of patients with divergent relapse rates. These groups account for the ∼80% of cases with VHL mutations and could be used to personalize adjuvant treatment discussions with patients as well as inform future adjuvant trial design.
Supplementary Figure 1 from Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target
Authors: Collins Colin C. , Volik Stanislav V. , Lapuk Anna V. , Wang Yuwei , Gout Peter W. , Wu Chunxiao , Xue Hui , Cheng Hongwei , Haegert Anne , Bell Robert H. , Brahmbhatt Sonal , Anderson Shawn , Fazli Ladan , Hurtado-Coll Antonio , Rubin Mark A. , Demichelis Francesca , Beltran Himisha , Hirst Martin , Marra Marco , Maher Christopher A. , Chinnaiyan Arul M. , Gleave Martin , Bertino Joseph R. , Lubin Martin , Wang Yuzhuo
Published: April 2023

PDF file - 576K, Immunohistochemical staining of patient #946's urethra metastasis (A) and LTL352 xenograft (B) for AR protein. Panels C and D show staining of the patient's urethra metastasis and xenograft respectively for TP63 protein.
Supplementary Table 1 from Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant
Authors: Samy Mona , Gattolliat Charles-Henry , Pendino Frédéric , Hillion Josette , Nguyen Eric , Bombard Sophie , Douc-Rasy Sétha , Bénard Jean , Ségal-Bendirdjian Evelyne
Published: April 2023

PDF file, 56K, Sequences and characteristics of gene-specific primers used for RT-PCR and genomic PCR.
Supplementary Methods and Figure Legend from Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant
Authors: Samy Mona , Gattolliat Charles-Henry , Pendino Frédéric , Hillion Josette , Nguyen Eric , Bombard Sophie , Douc-Rasy Sétha , Bénard Jean , Ségal-Bendirdjian Evelyne
Published: April 2023

PDF file, 81K.
Supplementary Figures 1-4 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Authors: Yap Timothy A. , Walton Mike I. , Hunter Lisa-Jane K. , Valenti Melanie , de Haven Brandon Alexis , Eve Paul D. , Ruddle Ruth , Heaton Simon P. , Henley Alan , Pickard Lisa , Vijayaraghavan Gowri , Caldwell John J. , Thompson Neil T. , Aherne Wynne , Raynaud Florence I. , Eccles Suzanne A. , Workman Paul , Collins Ian , Garrett Michelle D.
Published: April 2023

Supplementary Figures 1-4 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Supplementary Figure 4 from Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant
Authors: Samy Mona , Gattolliat Charles-Henry , Pendino Frédéric , Hillion Josette , Nguyen Eric , Bombard Sophie , Douc-Rasy Sétha , Bénard Jean , Ségal-Bendirdjian Evelyne
Published: April 2023

PDF file, 96K, Caspase-8 expression in MYCN-amplified SK-N-BE2 neuroblasts.
Supplementary Figure 6 from Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
Authors: Jazirehi Ali R. , Economou James S.
Published: April 2023

PDF file, 129KB, Deciphering the role of resistance-factors in immunosensitization.
Supplementary Figure 5 from Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
Authors: Jazirehi Ali R. , Economou James S.
Published: April 2023

PDF file, 473KB, NF-κB pathway is hyperactive in the resistant cells.
Supplementary Figure 4 from Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
Authors: Jazirehi Ali R. , Economou James S.
Published: April 2023

PDF file, 320KB, Levels of MART-1 required for recognition and killing of melanomas.
Supplementary Figure 3 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Authors: Hernandez-Davies Jenny E. , Zape Joan P. , Landaw Elliot M. , Tan Xiaolin , Presnell Ajia , Griffith Diana , Heinrich Michael C. , Glaser Keith B. , Sakamoto Kathleen M.
Published: April 2023

Supplementary Figure 3 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Supplementary Figure 3 from Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
Authors: Jazirehi Ali R. , Economou James S.
Published: April 2023

PDF file, 244KB, Sensitization of melanomas by specific pharmacological inhibitors.
Supplementary Figure 2 from Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
Authors: Jazirehi Ali R. , Economou James S.
Published: April 2023

PDF file, 42KB, Specific killing of melanomas by CTLs.
Supplementary Figure 1 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Authors: Hernandez-Davies Jenny E. , Zape Joan P. , Landaw Elliot M. , Tan Xiaolin , Presnell Ajia , Griffith Diana , Heinrich Michael C. , Glaser Keith B. , Sakamoto Kathleen M.
Published: April 2023

Supplementary Figure 1 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Supplementary Figure 1 from Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
Authors: Jazirehi Ali R. , Economou James S.
Published: April 2023

PDF file, 41KB, Broetzomib-mediated sensitization of melanomas to F5 CTL is MHC-I-restricted.
Supplementary Table 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Authors: Rivera Victor M. , Squillace Rachel M. , Miller David , Berk Lori , Wardwell Scott D. , Ning Yaoyu , Pollock Roy , Narasimhan Narayana I. , Iuliucci John D. , Wang Frank , Clackson Tim
Published: April 2023

Supplementary Table 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Supplementary Figure Legends 1-3 from Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma
Authors: Cloninger Cheri , Bernath Andrew , Bashir Tariq , Holmes Brent , Artinian Nicholas , Ruegg Teresa , Anderson Lauren , Masri Janine , Lichtenstein Alan , Gera Joseph
Published: April 2023

PDF file 47K
Supplementary Figure 3 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Authors: Rivera Victor M. , Squillace Rachel M. , Miller David , Berk Lori , Wardwell Scott D. , Ning Yaoyu , Pollock Roy , Narasimhan Narayana I. , Iuliucci John D. , Wang Frank , Clackson Tim
Published: April 2023

Supplementary Figure 3 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Supplementary Figure 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Authors: Rivera Victor M. , Squillace Rachel M. , Miller David , Berk Lori , Wardwell Scott D. , Ning Yaoyu , Pollock Roy , Narasimhan Narayana I. , Iuliucci John D. , Wang Frank , Clackson Tim
Published: April 2023

Supplementary Figure 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Supplementary Figure 1 from Enhanced Antitumor Effects by Chemical Modified IGb3 Analogues
Authors: Zhou Zhixia , Zhang Cai , Xia Chengfeng , Chen Wenlan , Zhu Huawei , Shang Pingping , Ma Fang , Wang Peng George , Zhang Jian , Xu Wenfang , Tian Zhigang
Published: April 2023

Supplementary Figure 1 from Enhanced Antitumor Effects by Chemical Modified IGb3 Analogues
Supplementary Table 1, Figure Legends 1-5 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Authors: Lund Per , Kotova Irina , Kedinger Valérie , Khanwalkar Harshal , Voltz Emilie , Hahn William C. , Gronemeyer Hinrich
Published: April 2023

Supplementary Table 1, Figure Legends 1-5 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Supplementary Figure 5 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Authors: Lund Per , Kotova Irina , Kedinger Valérie , Khanwalkar Harshal , Voltz Emilie , Hahn William C. , Gronemeyer Hinrich
Published: April 2023

Supplementary Figure 5 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Supplementary Figure Legend from MicroRNA Regulation of Oncolytic Adenovirus 6 for Selective Treatment of Castration-Resistant Prostate Cancer
Authors: Zhang Zhenwei , Zhang Xuemei , Newman Kam , Liu Xinyuan
Published: April 2023

PDF file, 89K.
Supplementary Figure 2 from MicroRNA Regulation of Oncolytic Adenovirus 6 for Selective Treatment of Castration-Resistant Prostate Cancer
Authors: Zhang Zhenwei , Zhang Xuemei , Newman Kam , Liu Xinyuan
Published: April 2023

PDF file, 28K, Low dose of cyclophosphamide increased antitumor efficacy of Ad6miR.
Supplementary Figure 1E-J from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Authors: Lund Per , Kotova Irina , Kedinger Valérie , Khanwalkar Harshal , Voltz Emilie , Hahn William C. , Gronemeyer Hinrich
Published: April 2023

Supplementary Figure 1E-J from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Supplementary Methods, Figures 1-5, Tables 1-3 from Tumor-Specific Targeting of Pancreatic Cancer with Shiga Toxin B-Subunit
Authors: Maak Matthias , Nitsche Ulrich , Keller Larissa , Wolf Petra , Sarr Marianne , Thiebaud Marine , Rosenberg Robert , Langer Rupert , Kleeff Jörg , Friess Helmut , Johannes Ludger , Janssen Klaus-Peter
Published: April 2023

PDF file - 313K
Supplementary Figure Legends 1-5 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
Authors: Hu Chaoxin , Lancaster Cynthia S. , Zuo Zhili , Hu Shuiying , Chen Zhaoyuan , Rubnitz Jeffrey E. , Baker Sharyn D. , Sparreboom Alex
Published: April 2023

PDF file - 53K
Supplementary Figure 5 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
Authors: Hu Chaoxin , Lancaster Cynthia S. , Zuo Zhili , Hu Shuiying , Chen Zhaoyuan , Rubnitz Jeffrey E. , Baker Sharyn D. , Sparreboom Alex
Published: April 2023

PDF file - 31K
Supplementary Figure Legends 1-4 from Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
Authors: Meier Timothy , Uhlik Mark , Chintharlapalli Sudhakar , Dowless Michele , Van Horn Robert , Stewart Julie , Blosser Wayne , Cook James , Young Debra , Ye Xiang , Evans Glenn , Credille Kelly , Ballard Darryl , Huber Lysiane , Capen Andrew , Chedid Marcio , Ilaria Robert , Smith Michele C. , Stancato Louis
Published: April 2023

PDF file - 56K
Supplementary Figure 3 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
Authors: Hu Chaoxin , Lancaster Cynthia S. , Zuo Zhili , Hu Shuiying , Chen Zhaoyuan , Rubnitz Jeffrey E. , Baker Sharyn D. , Sparreboom Alex
Published: April 2023

PDF file - 255K
Supplementary Figure 1 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
Authors: Hu Chaoxin , Lancaster Cynthia S. , Zuo Zhili , Hu Shuiying , Chen Zhaoyuan , Rubnitz Jeffrey E. , Baker Sharyn D. , Sparreboom Alex
Published: April 2023

PDF file - 46K
Supplementary Figure 3 from Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells
Authors: Rai Kammei , Takigawa Nagio , Ito Sachio , Kashihara Hiromi , Ichihara Eiki , Yasuda Tatsuji , Shimizu Kenji , Tanimoto Mitsune , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 3 from Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells
Supplementary Figure 1 from Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
Authors: Meier Timothy , Uhlik Mark , Chintharlapalli Sudhakar , Dowless Michele , Van Horn Robert , Stewart Julie , Blosser Wayne , Cook James , Young Debra , Ye Xiang , Evans Glenn , Credille Kelly , Ballard Darryl , Huber Lysiane , Capen Andrew , Chedid Marcio , Ilaria Robert , Smith Michele C. , Stancato Louis
Published: April 2023

PDF file - 313K
Supplementary Methods, Figures 1-4, Tables 1-2 from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
Authors: Squires Matthew , Ward George , Saxty Gordan , Berdini Valerio , Cleasby Anne , King Peter , Angibaud Patrick , Perera Tim , Fazal Lynsey , Ross Douglas , Jones Charlotte Griffiths , Madin Andrew , Benning Rajdeep K. , Vickerstaffe Emma , O'Brien Alistair , Frederickson Martyn , Reader Michael , Hamlett Christopher , Batey Michael A. , Rich Sharna , Carr Maria , Miller Darcey , Feltell Ruth , Thiru Abarna , Bethell Susanne , Devine Lindsay A. , Graham Brent L. , Pike Andrew , Cosme Jose , Lewis Edward J. , Freyne Eddy , Lyons John , Irving Julie , Murray Christopher , Newell David R. , Thompson Neil T.
Published: April 2023

PDF file - 475K
Supplementary Methods from Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis
Authors: Zhu Min , Saxton Romaine E. , Ramos Lillian , Chang David D. , Karlan Beth Y. , Gasson Judith C. , Slamon Dennis J.
Published: April 2023

Supplementary Methods from Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis
Supplementary Table 1 from Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer
Authors: Gioeli Daniel , Wunderlich Winfried , Sebolt-Leopold Judith , Bekiranov Stefan , Wulfkuhle Julia D. , Petricoin Emanuel F. , Conaway Mark , Weber Michael J.
Published: April 2023

Supplementary Table 1 from Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer
Supplementary Figure 1 from Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer
Authors: Gioeli Daniel , Wunderlich Winfried , Sebolt-Leopold Judith , Bekiranov Stefan , Wulfkuhle Julia D. , Petricoin Emanuel F. , Conaway Mark , Weber Michael J.
Published: April 2023

Supplementary Figure 1 from Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer
Supplementary Figure 1 from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
Authors: De Souza Raquel , Zahedi Payam , Badame Rose M. , Allen Christine , Piquette-Miller Micheline
Published: April 2023

Supplementary Figure 1 from Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer
Supplementary Table 1 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
Authors: Chen Chun-Te , Du Yi , Yamaguchi Hirohito , Hsu Jung-Mao , Kuo Hsu-Ping , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PDF file, 44K, Diet Information for HDF and ND.
Supplementary Figure Legend from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
Authors: Chen Chun-Te , Du Yi , Yamaguchi Hirohito , Hsu Jung-Mao , Kuo Hsu-Ping , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PDF file, 25K.
Supplementary Figure 2 from Cell Intrinsic Role of COX-2 in Pancreatic Cancer Development
Authors: Hill Reginald , Li Yunfeng , Tran Linh M. , Dry Sarah , Calvopina Joseph Hargan , Garcia Alejandro , Kim Christine , Wang Ying , Donahue Timothy R. , Herschman Harvey R. , Wu Hong
Published: April 2023

PDF file, 115K, P-AKT expression in Pdx1-Cre+;K-rasG12D/+;Ptenlox/+;Cox- 2lox/lox mice.
Supplementary Figure 4 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
Authors: Chen Chun-Te , Du Yi , Yamaguchi Hirohito , Hsu Jung-Mao , Kuo Hsu-Ping , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PDF file, 81K, Inflammatory infiltration analysis of mammary tumors.
Supplementary Figure 3 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
Authors: Chen Chun-Te , Du Yi , Yamaguchi Hirohito , Hsu Jung-Mao , Kuo Hsu-Ping , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PDF file, 348K, Inhibitors of the TNFα/IKKβ/mTOR/VEGF pathway block obesity-mediated tumorigenesis.
Supplementary Figure 2 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
Authors: Chen Chun-Te , Du Yi , Yamaguchi Hirohito , Hsu Jung-Mao , Kuo Hsu-Ping , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PDF file, 52K, Higher levels of circulating TNFα and VEGF in obese mice.
Supplementary Figure 1 from Targeting the IKKβ/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer
Authors: Chen Chun-Te , Du Yi , Yamaguchi Hirohito , Hsu Jung-Mao , Kuo Hsu-Ping , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PDF file, 47K, Dietary-induced obesity promotes breast cancer tumorigenesis.
Supplementary Figure Legends from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Authors: Piguet Anne-Christine , Saar Bettina , Hlushchuk Ruslan , St-Pierre Marie V. , McSheehy Paul M.J. , Radojevic Vesna , Afthinos Maresa , Terracciano Luigi , Djonov Valentin , Dufour Jean-François
Published: April 2023

Supplementary Figure Legends from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Supplementary Figure 3 from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Authors: Piguet Anne-Christine , Saar Bettina , Hlushchuk Ruslan , St-Pierre Marie V. , McSheehy Paul M.J. , Radojevic Vesna , Afthinos Maresa , Terracciano Luigi , Djonov Valentin , Dufour Jean-François
Published: April 2023

Supplementary Figure 3 from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Supplementary Figures 1-9 and Tables 1-3 from Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Authors: Bhagwat Shripad V. , Gokhale Prafulla C. , Crew Andrew P. , Cooke Andy , Yao Yan , Mantis Christine , Kahler Jennifer , Workman Jennifer , Bittner Mark , Dudkin Lorina , Epstein David M. , Gibson Neil W. , Wild Robert , Arnold Lee D. , Houghton Peter J. , Pachter Jonathan A.
Published: April 2023

Supplementary Figures 1-9 and Tables 1-3 from Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Supplementary Figure 1 from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Authors: Piguet Anne-Christine , Saar Bettina , Hlushchuk Ruslan , St-Pierre Marie V. , McSheehy Paul M.J. , Radojevic Vesna , Afthinos Maresa , Terracciano Luigi , Djonov Valentin , Dufour Jean-François
Published: April 2023

Supplementary Figure 1 from Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Supplementary Table 1 from Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma
Authors: McFarland Braden C. , Ma Jing-Yuan , Langford Catherine P. , Gillespie G. Yancey , Yu Hao , Zheng Ying , Nozell Susan E. , Huszar Dennis , Benveniste Etty N.
Published: April 2023

PDF file - 63K
Supplementary Figure 1 from Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma
Authors: McFarland Braden C. , Ma Jing-Yuan , Langford Catherine P. , Gillespie G. Yancey , Yu Hao , Zheng Ying , Nozell Susan E. , Huszar Dennis , Benveniste Etty N.
Published: April 2023

PDF file - 43K
Supplementary Tables 1-2 from Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines
Authors: Watson Venita Gresham , Hardison Nicholas E. , Harris Tyndall , Motsinger-Reif Alison , McLeod Howard L.
Published: April 2023

PDF file - 27K
Supplementary Figure Legends 1-3 from Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells
Authors: Alvero Ayesha B. , Montagna Michele K. , Holmberg Jennie C. , Craveiro Vinicius , Brown David , Mor Gil
Published: April 2023

Supplementary Figure Legends 1-3 from Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells
Supplementary Data Sets 1-5 from Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines
Authors: Watson Venita Gresham , Hardison Nicholas E. , Harris Tyndall , Motsinger-Reif Alison , McLeod Howard L.
Published: April 2023

PDF file - 981K
Supplementary Table 2 from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Authors: Yi Ping , Higa Arisa , Taouji Said , Bexiga Mariana G. , Marza Esther , Arma Daniela , Castain Claire , Le Bail Brigitte , Simpson Jeremy C. , Rosenbaum Jean , Balabaud Charles , Bioulac-Sage Paulette , Blanc Jean-Frédéric , Chevet Eric
Published: April 2023

PDF file - 36K, Quantification of eiF2α phosphorylation upon sorafenib treatment. X-ray film were quantified using scanning densitometry and data are represented as arbitrary units � SD.
Supplementary Table 1 from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Authors: Yi Ping , Higa Arisa , Taouji Said , Bexiga Mariana G. , Marza Esther , Arma Daniela , Castain Claire , Le Bail Brigitte , Simpson Jeremy C. , Rosenbaum Jean , Balabaud Charles , Bioulac-Sage Paulette , Blanc Jean-Frédéric , Chevet Eric
Published: April 2023

PDF file - 52K, PCR primers used in this study
Supplementary Table 1 from CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells
Authors: Tan Boon Shing , Tiong Kai Hung , Muruhadas Ashwin , Randhawa Nirmal , Choo Heng Lungh , Bradshaw Tracey D. , Stevens Malcolm F.G. , Leong Chee-Onn
Published: April 2023

PDF file - 55K
Supplementary Figures 1-4, Table 1 from Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells
Authors: Lovejoy Katherine S. , Serova Maria , Bieche Ivan , Emami Shahin , D'Incalci Maurizio , Broggini Massimo , Erba Eugenio , Gespach Christian , Cvitkovic Esteban , Faivre Sandrine , Raymond Eric , Lippard Stephen J.
Published: April 2023

PDF file - 539K
Supplementary Table 2 from DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma
Authors: Xu Xiao , Liu Rui-Fang , Zhang Xin , Huang Li-Yu , Chen Fei , Fei Qian-Lan , Han Ze-Guang
Published: April 2023

PDF file - 89K
Supplementary Materials and Methods from Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer
Authors: Wilson Peter M. , LaBonte Melissa J. , Lenz Heinz-Josef , Mack Philip C. , Ladner Robert D.
Published: April 2023

PDF file - 97K
Supplementary Figure 5 from DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma
Authors: Xu Xiao , Liu Rui-Fang , Zhang Xin , Huang Li-Yu , Chen Fei , Fei Qian-Lan , Han Ze-Guang
Published: April 2023

PDF file - 221K
Supplementary Figure 3 from Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer
Authors: Wilson Peter M. , LaBonte Melissa J. , Lenz Heinz-Josef , Mack Philip C. , Ladner Robert D.
Published: April 2023

PDF file - 188K
Supplementary Figure 4 from DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma
Authors: Xu Xiao , Liu Rui-Fang , Zhang Xin , Huang Li-Yu , Chen Fei , Fei Qian-Lan , Han Ze-Guang
Published: April 2023

PDF file - 174K
Supplementary Figure 1 from Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer
Authors: Wilson Peter M. , LaBonte Melissa J. , Lenz Heinz-Josef , Mack Philip C. , Ladner Robert D.
Published: April 2023

PDF file - 391K
Supplementary Figure 1 from DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma
Authors: Xu Xiao , Liu Rui-Fang , Zhang Xin , Huang Li-Yu , Chen Fei , Fei Qian-Lan , Han Ze-Guang
Published: April 2023

PDF file - 228K
Adobe PDF - 0728_sup_tables_1-3,_sup_figs_1-3.pdf from p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest
Authors: Zhang Keqiang , Wu Jun , Wu Xiwei , Wang Xiaochen , Wang Yan , Zhou Ning , Kuo Mei-ling , Liu Xiyong , Zhou Bingsen , Chang Lufen , Ann David , Yen Yun
Published: April 2023

Adobe PDF - 0728_sup_tables_1-3,_sup_figs_1-3.pdf from p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest
Supplementary Tables 1-3 from Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
Authors: Brave Sandra R. , Ratcliffe Kirsty , Wilson Zena , James Neil H. , Ashton Sue , Wainwright Anna , Kendrew Jane , Dudley Philippa , Broadbent Nicola , Sproat Graham , Taylor Sian , Barnes Claire , Silva Jeffrey C. , Farnsworth Charles L. , Hennequin Laurent , Ogilvie Donald J. , Jürgensmeier Juliane M. , Shibuya Masabumi , Wedge Stephen R. , Barry Simon T.
Published: April 2023

Supplementary Tables 1-3 from Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
Supplementary Table 1 from Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Authors: Kuramoto Takuya , Goto Hisatsugu , Mitsuhashi Atsushi , Tabata Sho , Ogawa Hirohisa , Uehara Hisanori , Saijo Atsuro , Kakiuchi Soji , Maekawa Yoichi , Yasutomo Koji , Hanibuchi Masaki , Akiyama Shin-ichi , Sone Saburo , Nishioka Yasuhiko
Published: April 2023

PDF file - 47K, Taqman gene expression assays
Supplementary Table 2 from RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma
Authors: Shimura Yuji , Kuroda Junya , Ri Masaki , Nagoshi Hisao , Yamamoto-Sugitani Mio , Kobayashi Tsutomu , Kiyota Miki , Nakayama Ryuko , Mizutani Shinsuke , Chinen Yoshiaki , Sakamoto Natsumi , Matsumoto Yosuke , Horiike Shigeo , Shiotsu Yukimasa , Iida Shinsuke , Taniwaki Masafumi
Published: April 2023

PDF file - 75K, Clinical information for patient-derived primary myeloma cells
Supplementary Figure 5 from Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Authors: Kuramoto Takuya , Goto Hisatsugu , Mitsuhashi Atsushi , Tabata Sho , Ogawa Hirohisa , Uehara Hisanori , Saijo Atsuro , Kakiuchi Soji , Maekawa Yoichi , Yasutomo Koji , Hanibuchi Masaki , Akiyama Shin-ichi , Sone Saburo , Nishioka Yasuhiko
Published: April 2023

PDF file - 174K, Dll4-Fc suppressed TNF-α induced NF-κB activity without attenuation of the cytoplasmic sequestration of NF-κB subunit
Supplementary Table 1 from RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma
Authors: Shimura Yuji , Kuroda Junya , Ri Masaki , Nagoshi Hisao , Yamamoto-Sugitani Mio , Kobayashi Tsutomu , Kiyota Miki , Nakayama Ryuko , Mizutani Shinsuke , Chinen Yoshiaki , Sakamoto Natsumi , Matsumoto Yosuke , Horiike Shigeo , Shiotsu Yukimasa , Iida Shinsuke , Taniwaki Masafumi
Published: April 2023

PDF file - 62K, Chromosomal abnormalities and signaling molecule expression in myeloma-derived cell lines
Supplementary Figure 4 from Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Authors: Kuramoto Takuya , Goto Hisatsugu , Mitsuhashi Atsushi , Tabata Sho , Ogawa Hirohisa , Uehara Hisanori , Saijo Atsuro , Kakiuchi Soji , Maekawa Yoichi , Yasutomo Koji , Hanibuchi Masaki , Akiyama Shin-ichi , Sone Saburo , Nishioka Yasuhiko
Published: April 2023

PDF file - 245K, Dll4-Fc promoted excessive angiogenesis of liver metastasis without affecting VEGFA expression and HUVECs proliferation
Supplementary Figure 3 from Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Authors: Kuramoto Takuya , Goto Hisatsugu , Mitsuhashi Atsushi , Tabata Sho , Ogawa Hirohisa , Uehara Hisanori , Saijo Atsuro , Kakiuchi Soji , Maekawa Yoichi , Yasutomo Koji , Hanibuchi Masaki , Akiyama Shin-ichi , Sone Saburo , Nishioka Yasuhiko
Published: April 2023

PDF file - 330K, Dll4-Fc reduced NF-κB/DNA binding in SBC-3 and H1048 cells
Supplementary Methods, Figure Legends 1-3 from Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth
Authors: Fishel Melissa L. , Jiang Yanlin , Rajeshkumar N.V. , Scandura Glenda , Sinn Anthony L. , He Ying , Shen Changyu , Jones David R. , Pollok Karen E. , Ivan Mircea , Maitra Anirban , Kelley Mark R.
Published: April 2023

Supplementary Methods, Figure Legends 1-3 from Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth
Supplementary Figure 2 from Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth
Authors: Fishel Melissa L. , Jiang Yanlin , Rajeshkumar N.V. , Scandura Glenda , Sinn Anthony L. , He Ying , Shen Changyu , Jones David R. , Pollok Karen E. , Ivan Mircea , Maitra Anirban , Kelley Mark R.
Published: April 2023

Supplementary Figure 2 from Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth
Supplementary Methods, Results, Figure 1, Tables 1-7 from Evaluating the Consistency of Differential Expression of MicroRNA Detected in Human Cancers
Authors: Gong Xue , Wu Ruihong , Wang Hongwei , Guo Xinwu , Wang Dong , Gu Yunyan , Zhang Yuannv , Zhao Wenyuan , Cheng Lixin , Wang Chenguang , Guo Zheng
Published: April 2023

Supplementary Methods, Results, Figure 1, Tables 1-7 from Evaluating the Consistency of Differential Expression of MicroRNA Detected in Human Cancers
Supplementary Table 1, Figures 1-5 from E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor
Authors: Ogino Hirokazu , Hanibuchi Masaki , Kakiuchi Soji , Trung Van The , Goto Hisatsugu , Ikuta Kenji , Yamada Tadaaki , Uehara Hisanori , Tsuruoka Akihiko , Uenaka Toshimitsu , Wang Wei , Li Qi , Takeuchi Shinji , Yano Seiji , Nishioka Yasuhiko , Sone Saburo
Published: April 2023

Supplementary Table 1, Figures 1-5 from E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor
Supplementary Tables 1-2, Figures 1-6 from Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin–like Growth Factor I Receptor Monoclonal Antibody
Authors: Shin Dong Hoon , Min Hye-Young , El-Naggar Adel K. , Lippman Scott M. , Glisson Bonnie , Lee Ho-Young
Published: April 2023

PDF file - 394K
Supplementary Figures 1-2 from In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen
Authors: Wang Xinning , Ma Dangshe , Olson William C. , Heston Warren D.W.
Published: April 2023

PDF file - 145K
Supplementary Figure Legends 1-3 from Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity
Authors: Zhao Qi , Feng Yang , Zhu Zhongyu , Dimitrov Dimiter S.
Published: April 2023

PDF file - 60K
Supplementary Methods, Figures 1-4 from The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma Cells
Authors: Klymenko Tetyana , Brandenburg Martin , Morrow Christopher , Dive Caroline , Makin Guy
Published: April 2023

PDF file - 240K
Supplementary Figure 2 from Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity
Authors: Zhao Qi , Feng Yang , Zhu Zhongyu , Dimitrov Dimiter S.
Published: April 2023

PDF file - 51K
Supplementary Figure Legend from Connexin-26 Is a Key Factor Mediating Gemcitabine Bystander Effect
Authors: Garcia-Rodríguez Laura , Pérez-Torras Sandra , Carrió Meritxell , Cascante Anna , García-Ribas Ignacio , Mazo Adela , Fillat Cristina
Published: April 2023

Supplementary Figure Legend from Connexin-26 Is a Key Factor Mediating Gemcitabine Bystander Effect
Supplementary Figure 1 from Connexin-26 Is a Key Factor Mediating Gemcitabine Bystander Effect
Authors: Garcia-Rodríguez Laura , Pérez-Torras Sandra , Carrió Meritxell , Cascante Anna , García-Ribas Ignacio , Mazo Adela , Fillat Cristina
Published: April 2023

Supplementary Figure 1 from Connexin-26 Is a Key Factor Mediating Gemcitabine Bystander Effect
Supplementary Tables 1-4 from Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Authors: Jing Junping , Greshock Joel , Holbrook Joanna Dawn , Gilmartin Aidan , Zhang Xiping , McNeil Elizabeth , Conway Theresa , Moy Christopher , Laquerre Sylvie , Bachman Kurt , Wooster Richard , Degenhardt Yan
Published: April 2023

PDF file - 388K
Supplementary Figure Legend from Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
Authors: Tai Sheng , Sun Yin , Liu Nan , Ding Boxiao , Hsia Elaine , Bhuta Sunita , Thor Ryan K. , Damoiseaux Robert , Liang Chaozhao , Huang Jiaoti
Published: April 2023

PDF file, 70KB.
Supplementary Figure 2 from Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
Authors: Tai Sheng , Sun Yin , Liu Nan , Ding Boxiao , Hsia Elaine , Bhuta Sunita , Thor Ryan K. , Damoiseaux Robert , Liang Chaozhao , Huang Jiaoti
Published: April 2023

PDF file, 258KB, Cell-cycle distribution histograms.
Supplementary Figure 1 from Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
Authors: Tai Sheng , Sun Yin , Liu Nan , Ding Boxiao , Hsia Elaine , Bhuta Sunita , Thor Ryan K. , Damoiseaux Robert , Liang Chaozhao , Huang Jiaoti
Published: April 2023

PDF file, 66KB, Mixture-Algebraic estimate analysis of the combination index (CI) values.
Supplementary Table 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Authors: Hegi Monika E. , Diserens Annie-Claire , Bady Pierre , Kamoshima Yuta , Kouwenhoven Mathilde C. M. , Delorenzi Mauro , Lambiv Wanyu L. , Hamou Marie-France , Matter Matthias S. , Koch Arend , Heppner Frank L. , Yonekawa Yasuhiro , Merlo Adrian , Frei Karl , Mariani Luigi , Hofer Silvia
Published: April 2023

Supplementary Table 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Supplementary Methods, Figure Legends 1-5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Authors: Hegi Monika E. , Diserens Annie-Claire , Bady Pierre , Kamoshima Yuta , Kouwenhoven Mathilde C. M. , Delorenzi Mauro , Lambiv Wanyu L. , Hamou Marie-France , Matter Matthias S. , Koch Arend , Heppner Frank L. , Yonekawa Yasuhiro , Merlo Adrian , Frei Karl , Mariani Luigi , Hofer Silvia
Published: April 2023

Supplementary Methods, Figure Legends 1-5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Supplementary Figure 5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Authors: Hegi Monika E. , Diserens Annie-Claire , Bady Pierre , Kamoshima Yuta , Kouwenhoven Mathilde C. M. , Delorenzi Mauro , Lambiv Wanyu L. , Hamou Marie-France , Matter Matthias S. , Koch Arend , Heppner Frank L. , Yonekawa Yasuhiro , Merlo Adrian , Frei Karl , Mariani Luigi , Hofer Silvia
Published: April 2023

Supplementary Figure 5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Supplementary Figure 4 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Authors: Hegi Monika E. , Diserens Annie-Claire , Bady Pierre , Kamoshima Yuta , Kouwenhoven Mathilde C. M. , Delorenzi Mauro , Lambiv Wanyu L. , Hamou Marie-France , Matter Matthias S. , Koch Arend , Heppner Frank L. , Yonekawa Yasuhiro , Merlo Adrian , Frei Karl , Mariani Luigi , Hofer Silvia
Published: April 2023

Supplementary Figure 4 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Supplementary Figure 4 cont. from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Authors: Hegi Monika E. , Diserens Annie-Claire , Bady Pierre , Kamoshima Yuta , Kouwenhoven Mathilde C. M. , Delorenzi Mauro , Lambiv Wanyu L. , Hamou Marie-France , Matter Matthias S. , Koch Arend , Heppner Frank L. , Yonekawa Yasuhiro , Merlo Adrian , Frei Karl , Mariani Luigi , Hofer Silvia
Published: April 2023

Supplementary Figure 4 cont. from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Supplementary Figure 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Authors: Hegi Monika E. , Diserens Annie-Claire , Bady Pierre , Kamoshima Yuta , Kouwenhoven Mathilde C. M. , Delorenzi Mauro , Lambiv Wanyu L. , Hamou Marie-France , Matter Matthias S. , Koch Arend , Heppner Frank L. , Yonekawa Yasuhiro , Merlo Adrian , Frei Karl , Mariani Luigi , Hofer Silvia
Published: April 2023

Supplementary Figure 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Supplementary Figure 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Authors: Hegi Monika E. , Diserens Annie-Claire , Bady Pierre , Kamoshima Yuta , Kouwenhoven Mathilde C. M. , Delorenzi Mauro , Lambiv Wanyu L. , Hamou Marie-France , Matter Matthias S. , Koch Arend , Heppner Frank L. , Yonekawa Yasuhiro , Merlo Adrian , Frei Karl , Mariani Luigi , Hofer Silvia
Published: April 2023

Supplementary Figure 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Supplementary Figure Legend from Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Authors: Dolloff Nathan G. , Allen Joshua E. , Dicker David T. , Aqui Nicole , Vogl Dan , Malysz Jozef , Talamo Giampaolo , El-Deiry Wafik S.
Published: April 2023

PDF file, 92K.
Supplementary Figure Legend from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Authors: Awasthi Niranjan , Zhang Changhua , Ruan Winston , Schwarz Margaret A. , Schwarz Roderich E.
Published: April 2023

PDF file - 28K
Supplementary Figure 6 from Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Authors: Dolloff Nathan G. , Allen Joshua E. , Dicker David T. , Aqui Nicole , Vogl Dan , Malysz Jozef , Talamo Giampaolo , El-Deiry Wafik S.
Published: April 2023

PDF file, 77K, SLM6 shows combinatorial activity with bortezomib.
Supplementary Figure 5 from Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Authors: Dolloff Nathan G. , Allen Joshua E. , Dicker David T. , Aqui Nicole , Vogl Dan , Malysz Jozef , Talamo Giampaolo , El-Deiry Wafik S.
Published: April 2023

PDF file, 107K, SLM6 is a potent and direct inhibitor of CDK9, CDK1, and CDK2.
Supplementary Figure Legend from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Authors: Yo Yi-Te , Lin Ya-Wen , Wang Yu-Chi , Balch Curt , Huang Rui-Lan , Chan Michael W.Y. , Sytwu Huey-Kang , Chen Chi-Kuan , Chang Cheng-Chang , Nephew Kenneth P. , Huang Tim , Yu Mu-Hsien , Lai Hung-Cheng
Published: April 2023

PDF file, 82KB.
Supplementary Figure 3 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Authors: Yo Yi-Te , Lin Ya-Wen , Wang Yu-Chi , Balch Curt , Huang Rui-Lan , Chan Michael W.Y. , Sytwu Huey-Kang , Chen Chi-Kuan , Chang Cheng-Chang , Nephew Kenneth P. , Huang Tim , Yu Mu-Hsien , Lai Hung-Cheng
Published: April 2023

PDF file, 4382KB, One day after inoculation of 1�106 CP70 cells in NOD/SCID mice, niclosamide (10mg/kg/day) was administered intraperitoneally for three weeks, then twice a week for 2 weeks. After 9 weeks, mice were sacrificed, and tumor size/incidence assessed. (A) Red lines outline the peritoneal tumors. (B) Comparison of tumor formation after dissecting all tumors.